A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Purpose: CPI-613, a lipoate analogue that inhibits pyruvate dehydrogenase (PDH) and α-ketogluterate dehydrogenase (KGDH), has activity in patients with myeloid malignancies. This study explored the role of mitochondrial metabolism in chemotherapy response and determined the MTD, efficacy, and safety of CPI-613 combined with high-dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia. Experimental Design: The role of mitochondrial response to chemotherapy was assessed in cell lines and animal models. A phase I study of CPI-613 plus cytarabine and mitoxantrone was conducted in patients with relapsed or refractory AML. Results: Exposure to chemotherapy induced mitochondrial oxygen consumption that depended on PDH. CPI-613 sensitized AML cells to chemotherapy indicating that mitochondrial metabolism is a source of resistance. Loss of p53 did not alter response to CPI-613. The phase I study enrolled 67 patients and 62 were evaluable for response. The overall response rate was 50% (26CR+5CRi/62). Median survival was 6.7 months. In patients over 60 years old, the CR/CRi rate was 47% (15/32) with a median survival of 6.9 months. The response rate for patients with poor-risk cytogenetics also was encouraging with 46% (11/24 patients) achieving a CR or CRi. RNA sequencing analysis of a subset of baseline bone marrow samples revealed a gene expression signature consistent with the presence of B cells in the pretreatment marrow of responders. Conclusions: The addition of CPI-613 to chemotherapy is a promising approach in older patients and those with poor-risk cytogenetics. Clin Cancer Res; 24(9); 2060–73. ©2018 AACR.

[1]  M. Selak,et al.  Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment. , 2017, Cell metabolism.

[2]  N. Hempel,et al.  Insights into the Dichotomous Regulation of SOD2 in Cancer , 2017, Antioxidants.

[3]  Eyal Gottlieb,et al.  Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemic stem cells , 2017, Nature Medicine.

[4]  M. Carroll,et al.  Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. , 2017, Cancer discovery.

[5]  Gary D Bader,et al.  Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. , 2017, Blood.

[6]  N. Larsson,et al.  Mammalian Mitochondria and Aging: An Update. , 2017, Cell metabolism.

[7]  K. Haas,et al.  PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors , 2016, Cancer Immunology Research.

[8]  Steven M. Chan,et al.  Isocitrate dehydrogenase mutations in myeloid malignancies , 2016, Leukemia.

[9]  Sang-Min Jeon,et al.  Regulation and function of AMPK in physiology and diseases , 2016, Experimental & Molecular Medicine.

[10]  B. Nicklas,et al.  Blood-cell bioenergetics are associated with physical function and inflammation in overweight/obese older adults , 2015, Experimental Gerontology.

[11]  J. Velasco,et al.  Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and lung cancer. , 2015, Free radical biology & medicine.

[12]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[13]  L. Miller,et al.  A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies , 2014, Clinical Cancer Research.

[14]  P. Bingham,et al.  A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process , 2014, Cancer & metabolism.

[15]  S. Isom,et al.  High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. , 2015, Leukemia research.

[16]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[17]  Liu Wei,et al.  LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.

[18]  W. Gmeiner,et al.  Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. , 2011, Blood.

[19]  P. Bingham,et al.  Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo , 2011, Journal of Molecular Medicine.

[20]  S. Lowe,et al.  Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. , 2011, Experimental hematology.

[21]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[22]  K. Kaluarachchi,et al.  Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. , 2010, The Journal of clinical investigation.

[23]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[24]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[25]  David Bryant,et al.  DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists , 2007, Nucleic Acids Res..

[26]  Alexander R. Abbas,et al.  Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data , 2005, Genes and Immunity.

[27]  J. Bennett,et al.  Long‐term survival in acute myeloid leukemia , 1997, Cancer.

[28]  J. Yates,et al.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. , 1973, Cancer chemotherapy reports.

[29]  Xiaoyan Xin,et al.  miR-146a Inhibits Proliferation and Enhances Chemosensitivity in Epithelial Ovarian Cancer via Reduction of SOD2. , 2016, Oncology research.

[30]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[31]  E. Podack,et al.  B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion , 2012, Cancer Immunology, Immunotherapy.

[32]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.